Literature DB >> 24383522

Population pharmacometrics in support of analgesics studies.

P Välitalo1, V-P Ranta, A C Hooker, M Kokki, H Kokki.   

Abstract

Population pharmacometric modeling is used to explain both population trends as well as the sources and magnitude of variability in pharmacokinetic and pharmacodynamics data; the later, in part, by taking into account patient characteristics such as weight, age, renal function and genetics. The approach is best known for its ability to analyze sparse data, i.e. when only a few measurements have been collected from each subject, but other benefits include its flexibility and the potential to construct more detailed models than those used in the traditional individual curve fitting approach. This review presents the basic concepts of population pharmacokinetic and pharmacodynamic modeling and includes several analgesic drug examples. In addition, the use of these models to design and optimize future studies is discussed. In this context, finding the best design factors, such as the sampling times or the dose, for future studies within pre-defined criteria using a previously constructed population pharmacokinetic model can help researchers acquire clinically meaningful data without wasting resources and unnecessarily exposing vulnerable patient groups to study drugs and additional blood sampling.
© 2014 The Acta Anaesthesiologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24383522     DOI: 10.1111/aas.12253

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  6 in total

1.  Toward a comprehensive model of ∆(9)-tetrahydrocannabinol pharmacokinetics using a population pharmacokinetics approach.

Authors:  Brett C Ginsburg
Journal:  Clin Pharmacokinet       Date:  2015-02       Impact factor: 6.447

2.  Pharmacokinetics of intravenous sildenafil in children with palliated single ventricle heart defects: effect of elevated hepatic pressures.

Authors:  Kevin D Hill; Mario R Sampson; Jennifer S Li; Robert D Tunks; Scott R Schulman; Michael Cohen-Wolkowiez
Journal:  Cardiol Young       Date:  2015-04-01       Impact factor: 1.093

Review 3.  Simulation Models for Prediction of Bioavailability of Medicinal Drugs-the Interface Between Experiment and Computation.

Authors:  Mahmoud E Soliman; Adeniyi T Adewumi; Oluwole B Akawa; Temitayo I Subair; Felix O Okunlola; Oluwayimika E Akinsuku; Shahzeb Khan
Journal:  AAPS PharmSciTech       Date:  2022-03-15       Impact factor: 3.246

Review 4.  Epidural Oxycodone for Acute Pain.

Authors:  Panu Piirainen; Hannu Kokki; Merja Kokki
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-23

5.  Bioavailability of oxycodone by mouth in coronary artery bypass surgery patients - a randomized trial.

Authors:  Antti Valtola; James D Morse; Pawel Florkiewicz; Heidi Hautajärvi; Pasi Lahtinen; Tadeusz Musialowicz; Brian J Anderson; Veli-Pekka Ranta; Hannu Kokki
Journal:  J Drug Assess       Date:  2020-07-28

Review 6.  In Vitro Dissolution and in Silico Modeling Shortcuts in Bioequivalence Testing.

Authors:  Moawia M Al-Tabakha; Muaed J Alomar
Journal:  Pharmaceutics       Date:  2020-01-04       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.